GenoMed Seeks Volunteers for Possible Cancer Treatment
ST. LOUIS, Jan. 16 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based genomics company, announced today that it is seeking volunteers with any common cancer (other than prostate or breast cancer), at any stage, to test a new medication in addition to their current medications.
GenoMed has discovered that a safe class of drugs called ACE inhibitors may be useful for many serious diseases, including most common cancers. ACE stands for "angiotensin converting enzyme."
GenoMed has found that patients with most common cancers tend to have overactivity of their ACE enzyme. A logical approach is to inhibit ACE, using an ACE inhibitor. This clinical trial in no way is intended to replace current chemotherapy, but to add to it in the hope of achieving better patient outcomes.
The research supporting this new treatment approach was published in October, 2002 in Diabetes Technology and Therapeutics.
GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease.
To volunteer, please contact GenoMed's Chief Medical Officer, Dr. David Moskowitz, tel. 314-977-0110, fax 928-395-2580, email: dwmoskowitz@genomedics.com or visit GenoMed at www.genomedics.com.
SOURCE GenoMed, Inc.
CONTACT: Dr. David Moskowitz, Chief Medical Officer of GenoMed, Inc.,
+1-314-977-0110, or fax, +1-928-395-2580, or dwmoskowitz@genomedics.com/
Web site: genomedics.com
. |
